BHVN Biohaven Pharmaceutical Holding Company Ltd. Stock Quote

BHVN [NYSE]

Biohaven Pharmaceutical Holding Company Ltd.

Index	-	P/E	-	EPS (ttm)	-12.27	Insider Own	8.60%	Shs Outstand	59.68M	Perf Week	5.60%
Market Cap	5.09B	Forward P/E	-	EPS next Y	-9.78	Insider Trans	-1.70%	Shs Float	49.54M	Perf Month	-0.82%
Income	-698.30M	PEG	-	EPS next Q	-2.97	Inst Own	-	Short Float	10.69%	Perf Quarter	-12.62%
Sales	28.50M	P/S	178.69	EPS this Y	-77.40%	Inst Trans	-1.78%	Short Ratio	9.98	Perf Half Y	41.50%
Book/sh	-3.56	P/B	-	EPS next Y	20.80%	ROA	-134.10%	Target Price	95.91	Perf Year	95.78%
Cash/sh	9.20	P/C	9.32	EPS next 5Y	-	ROE	-	52W Range	26.56 - 100.77	Perf YTD	0.05%
Dividend	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-14.91%	Beta	1.04
Dividend %	-	Quick Ratio	3.20	Sales past 5Y	-	Gross Margin	72.90%	52W Low	222.85%	ATR	4.38
Employees	647	Current Ratio	3.30	Sales Q/Q	-	Oper. Margin	-	RSI (14)	52.84	Volatility	6.38% 4.66%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	-60.70%	Profit Margin	-	Rel Volume	1.22	Prev Close	80.90
Shortable	Yes	LT Debt/Eq	-	Earnings	-	Payout	-	Avg Volume	531.04K	Price	85.75
Recom	1.70	SMA20	1.15%	SMA50	-0.14%	SMA200	15.25%	Volume	650,606	Change	6.00%

Dec-15-20

Initiated

H.C. Wainwright

Buy

$121

Apr-17-20

Initiated

Cowen

Outperform

$45

Feb-10-20

Downgrade

Oppenheimer

Outperform → Perform

Feb-06-20

Initiated

Mizuho

Buy

Nov-22-19

Initiated

Wedbush

Outperform

Jun-25-19

Reiterated

Canaccord Genuity

Buy

$89 → $84

May-06-19

Initiated

Goldman

Buy

$92

Apr-09-19

Downgrade

Morgan Stanley

Overweight → Equal-Weight

Mar-04-19

Reiterated

Needham

Buy

$48 → $56

Jul-03-18

Reiterated

Needham

Buy

$36 → $48

Jul-02-18

Reiterated

Needham

Buy

$36 → $48

Apr-05-18

Downgrade

Barclays

Overweight → Equal Weight

$30 → $25

Feb-22-18

Reiterated

Canaccord Genuity

Buy

$30 → $39

Dec-15-17

Initiated

Canaccord Genuity

Buy

$30

Oct-03-17

Reiterated

Needham

Buy

$43 → $36

Feb-23-21 06:40PM	Biohaven To Report Fourth Quarter And Full Year 2020 Financial Results And Recent Business Developments On March 1, 2021 PR Newswire
Feb-22-21 07:30AM	Biohaven's BHV-1200, A Multimodal Antibody Therapy Enhancer (MATE), Demonstrates Effective Neutralization Of Multiple Strains Of COVID-19 PR Newswire -5.15%
Feb-08-21 07:30AM	Biohaven Provides Update On ESG Practices PR Newswire
Jan-25-21 07:30AM	Biohaven Announces Preliminary 4Q2020 Net Product Revenue For NURTEC® ODT PR Newswire +8.52%
Jan-20-21 12:13PM	Biotech Stock Roundup: ALXN Pauses Study, ACRS & GRTS Surge, & Other Updates Zacks
Jan-19-21 04:12PM	Biohaven Dives After Experimental Alzheimer's Treatment Flops In Key Test Investor's Business Daily -8.34%
10:22AM	Biohaven (BHVN) Falls as Troriluzole Fails in Alzheimer's Study Zacks
Jan-18-21 10:10AM	Biohaven Signs Cody Ware as Driver for Nurtec® ODT Chevrolet for the 2021 NASCAR Cup Series Season PR Newswire
09:00AM	Biohaven Provides Update On Phase 2/3 Trial And Alzheimer's Disease Program PR Newswire
Jan-07-21 07:30AM	Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs PR Newswire
Jan-05-21 10:00AM	Biohaven's Nurtec® ODT Partners with Rick Ware Racing for 24 Hours of Daytona Entry PR Newswire
09:08AM	Biohaven (BHVN) Initiates Pivotal Study on OCD Candidate Zacks
Jan-04-21 07:30AM	Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder PR Newswire
Dec-30-20 08:49AM	Are Options Traders Betting on a Big Move in Biohaven (BHVN) Stock? Zacks
Dec-21-20 05:18PM	Is BHVN A Good Stock To Buy According To Hedge Funds? Insider Monkey
Dec-16-20 07:30AM	Biohaven's Rimegepant For Preventive Treatment Of Migraine Published In The Lancet PR Newswire
Dec-07-20 10:00AM	Kleo Pharmaceuticals Presents Preclinical Data on KPMW135, a Novel CD3 x CD20 Bispecific Version of Rituximab, Showing Increased Anti-Tumor Activity Compared to Rituximab, at The 62nd Annual American Society of Hematology (ASH) Meeting GlobeNewswire
Dec-03-20 12:33PM	Is Biohaven Pharmaceutical (BHVN) a Smart Long-term Buy? Insider Monkey
Dec-02-20 10:05AM	Biohaven's Nurtec ODT Partners with the Rick Ware Racing Team in the 2021 NASCAR Cup Series PR Newswire
Nov-30-20 08:00AM	Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE) at The 62nd Annual Society of Hematology (ASH) Meeting GlobeNewswire
Nov-22-20 09:32PM	BioShin enrolls first patient into an Asia-Pacific regional multi-center phase III clinical trial of rimegepant (BHV-3000) for the acute treatment of migraine. GlobeNewswire
Nov-19-20 09:51AM	Biohaven Pharmaceutical Could Pull Back From Here TheStreet.com
Nov-16-20 09:00AM	Value-based agreement between Prime Therapeutics and Biohaven aims to bring NURTEC ODT acute migraine treatment financial protection to health plans PR Newswire
07:30AM	Biohaven Pharmaceuticals And Weill Cornell Medicine Collaborate To Initiate Proof Of Concept Trial With CGRP Receptor Antagonist In Plaque Psoriasis PR Newswire
Nov-11-20 04:30PM	Biohaven Pharmaceuticals Inaugural Partner Of National Ataxia Foundation's Drug Development Collaborative PR Newswire +7.57%
Nov-10-20 10:39AM	Biohaven (BHVN) Q3 Earnings Miss, Nurtec Uptake Promising Zacks +6.44%
Nov-09-20 08:32AM	Recap: Biohaven Pharmaceutical Q3 Earnings Benzinga
08:00AM	Kleo Pharmaceuticals Presents Preclinical Proof-of-Concept Data on a Novel Chemical Conjugation Platform (MATE) at the Society for Immunotherapy of Cancer's (SITC) 35th Annual Meeting GlobeNewswire
08:00AM	Biohaven Reports Third Quarter 2020 Financial Results and Recent Business Developments PR Newswire
06:30AM	Biohaven Pharmaceutical Holding Co. Ltd. to Host Earnings Call ACCESSWIRE
Nov-06-20 08:34AM	Why Earnings Season Could Be Great for Biohaven (BHVN) Zacks
Nov-02-20 09:15AM	5 Drug/Biotech Stocks Set to Outpace Q3 Earnings Estimates Zacks
Oct-30-20 06:23PM	Biohaven To Report Third Quarter 2020 Financial Results And Recent Business Developments On November 9, 2020 PR Newswire
Oct-29-20 12:51PM	Kleo Pharmaceuticals Announces Data Presentation on Novel Conjugation Platform at the Society for Immunotherapy of Cancer's (SITC) 35th Annual Meeting GlobeNewswire
Oct-27-20 12:28PM	Were Hedge Funds Right About Biohaven Pharma (BHVN)? Insider Monkey
Oct-15-20 11:41AM	FDA Accepts Biohaven's (BHVN) sNDA for Migraine Drug Nurtec Zacks
Oct-14-20 07:30AM	U.S. FDA Accepts Biohaven's Supplemental New Drug Application (sNDA) Of NURTEC ODT For The Preventive Treatment Of Migraine PR Newswire
Oct-04-20 09:19AM	If You Had Bought Biohaven Pharmaceutical Holding (NYSE:BHVN) Stock Three Years Ago, You Could Pocket A 103% Gain Today Simply Wall St.
09:19AM	If You Had Bought Biohaven Pharmaceutical Holding (NYSE:BHVN) Stock Three Years Ago, You Could Pocket A 103% Gain Today CoinDesk
Sep-28-20 07:00AM	BioShin, Biohaven's Asia-Pacific Subsidiary, Raises $60M in Series A Funding to Advance Neuroscience Pipeline in Asia-Pacific Region PR Newswire
Sep-21-20 08:00AM	Kleo Pharmaceuticals to Present at Bioscience Pipeline & Innovation in Connecticut in the Age of COVID Conference GlobeNewswire -6.06%
Sep-10-20 07:00AM	Biohaven's Oral Zavegepant, A Third Generation CGRP Receptor Antagonist, Receives Authorization To Proceed From FDA And Achieves First In Human Dosing PR Newswire
Sep-08-20 08:30AM	Kleo Pharmaceuticals Announces Orphan Drug Designation for KP1237 in Multiple Myeloma GlobeNewswire
04:34AM	BiohavenPharmaHldg Reaches 80-Plus Relative Strength Rating Benchmark Investor's Business Daily
Sep-02-20 01:19PM	Hedge Funds Have Been This Bullish On Biohaven Pharmaceutical (BHVN) Insider Monkey
Aug-10-20 11:55AM	Biohaven (BHVN) Q2 Earnings Beat on Strong Nurtec Uptake Zacks -8.22%
07:45AM	Biohaven Reports Second Quarter 2020 Financial Results And Recent Business Developments PR Newswire
Aug-07-20 09:47AM	Biohaven Announces up to $500 Million Non-Dilutive Term Loan with Sixth Street PR Newswire +6.67%
09:37AM	Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million PR Newswire
Aug-06-20 01:42PM	Early Sales of Eli Lilly's Migraine Drug Disappoint GuruFocus.com
Aug-05-20 05:00PM	Biohaven Pharmaceutical To Report Second Quarter 2020 Financial Results And Recent Business Developments On August 10, 2020 PR Newswire
Aug-03-20 08:00AM	Biohaven Announces Enrollment Of First Patients In Pivotal HEALEY ALS Platform Trial Including Verdiperstat Conducted By Healey Center For ALS At Massachusetts General Hospital PR Newswire
Jul-21-20 07:30AM	Biohaven Completes Enrollment Ahead of Timelines in International Phase 3 Clinical Trial of Verdiperstat in Multiple System Atrophy PR Newswire
Jul-16-20 07:52AM	Taking a Wait and Watch Strategy on Biohaven Pharmaceutical TheStreet.com
05:45AM	Biohaven Pharmaceutical's Migraine Drug To Be Promoted by Khloe Kardashian Benzinga
Jul-15-20 11:41AM	Biohaven and Khloe Kardashian Team to Promote Migraine Drug TheStreet.com
09:52AM	Khloe Kardashian Adds Biohaven Migraine Drug to Brand Touts Bloomberg
07:30AM	After Living with Migraine for Years, Khloé Kardashian Leads Biohaven's Take Back Today Campaign to Empower People with Migraine PR Newswire
Jul-13-20 10:08AM	Did Hedge Funds Make The Right Call On Biohaven Pharmaceutical Holding Company Ltd. (BHVN) ? Insider Monkey -6.19%
Jul-08-20 07:30AM	Kleo Pharmaceuticals Announces $5 Million Grant to Advance Development of COVID-19 Hyperimmune Globulin Mimic (HGM) as a Therapeutic for Infected Patients GlobeNewswire +8.14%
Jun-24-20 07:00AM	Biohaven Announces Obsessive-Compulsive Disorder (OCD) Proof Of Concept Phase 2/3 Study Results And Program Update PR Newswire
Jun-16-20 07:00AM	Biohaven Presents NURTEC (rimegepant) Clinical and Pharmacoeconomic Data at the American Headache Society (AHS) Virtual Annual Scientific Meeting PR Newswire
Jun-10-20 07:00AM	Biohaven Appoints Bob Hugin to its Board of Directors PR Newswire
Jun-08-20 02:13AM	Is Biohaven Pharmaceutical Holding Company Ltd. (BHVN) A Good Stock To Buy? Insider Monkey
Jun-01-20 04:05PM	Kleo Pharmaceuticals to Present Corporate Overview and Pipeline Update at Jefferies Virtual Healthcare Conference GlobeNewswire
May-28-20 06:46AM	3 Reasons Why Biohaven Pharmaceuticals' Stock Is Taking Off Motley Fool
May-21-20 07:30AM	Kleo Pharmaceuticals and Celularity Enter into Research Collaboration to Rapidly Develop Allogeneic NK Cell Combination Therapies for COVID-19 and Multiple Myeloma GlobeNewswire
May-18-20 07:30AM	Biohaven Showcases Clinical and Pharmacoeconomic Data for NURTEC ODT (rimegepant) with 25 Presentations on the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform PR Newswire +6.81%
May-15-20 07:33AM	Kleo Pharmaceuticals to Present Preclinical Data Highlighting the Synergistic Potential of Kleo Asset KP1237 and Autologous NK Cells in the Treatment of Multiple Myeloma at the 2020 American Society of Clinical Oncology Virtual Meeting GlobeNewswire +6.66%
May-07-20 04:10PM	Biohaven Pharmaceuticals Reports First Quarter 2020 Financial Results and Recent Business Developments PR Newswire
May-04-20 08:47AM	Why Biohaven (BHVN) Might Surprise This Earnings Season Zacks +8.34%
Apr-27-20 07:30AM	Biohaven Enters Into Agreement With Genpharm for Distribution of NURTEC ODT in the Middle East PR Newswire
Apr-16-20 05:42PM	Biohaven Changing 2020 Annual Meeting Of Shareholders To Virtual-Only Meeting Format Due To COVID-19 PR Newswire
07:30AM	Biohaven Enters Into Partnership With Medison Pharma To Distribute NURTEC ODT In Israel PR Newswire
Apr-09-20 10:01AM	Biohaven Pharmaceutical Needs More Bottom Development Before Becoming a Buy TheStreet.com +7.38%
07:30AM	Biohaven Receives FDA May Proceed Letter to Begin Phase 2 Trial of Intranasal Vazegepant to Treat Lung Inflammation After COVID-19 Infection PR Newswire
Apr-07-20 07:48AM	Does Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) Have A High Beta? Simply Wall St. -5.77%
07:30AM	Biohaven Enters Into Collaboration With Cove, Leading Migraine Telemedicine Platform, To Enhance Accessibility Of NURTEC ODT PR Newswire
Mar-31-20 07:33AM	Kleo Pharmaceuticals Enters into Research Collaboration with Green Cross LabCell (GCLC) To Rapidly Develop COVID-19-Targeting Allogeneic NK Cell Combination Therapy PR Newswire
Mar-30-20 07:30AM	Biohaven Achieves Positive Results in Pivotal Trial of Oral NURTEC, Dosed Every Other Day, for the Preventive Treatment of Migraine PR Newswire -5.58%
Mar-29-20 08:21PM	Hedge Funds Are Souring On Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Insider Monkey
Mar-23-20 07:30AM	Biohaven to Advance Vazegepant into Phase 3 for the Acute Treatment of Migraine Following Successful End of Phase 2 Meeting with FDA PR Newswire
Mar-18-20 07:30AM	Biohaven's Verdiperstat Receives Fast Track Designation For The Treatment Of Multiple System Atrophy PR Newswire
Mar-13-20 07:30AM	Biohaven Announces Patient Savings Program Where Patients Can Pay as Little as $0 for NURTEC ODT (rimegepant 75 mg) for the Acute Treatment of Migraine in Adults PR Newswire +5.80%
Mar-12-20 04:30PM	Biohaven's NURTEC ODT (rimegepant 75mg) is Now Available in U.S. Pharmacies for the Acute Treatment of Migraine in Adults PR Newswire -14.80%
Mar-04-20 09:55AM	Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More Zacks +6.23%
Feb-28-20 07:28AM	The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO Benzinga +8.18%
Feb-27-20 04:11PM	Biohaven's NURTEC ODT (rimegepant) Receives FDA Approval for the Acute Treatment of Migraine in Adults PR Newswire -8.54%
Feb-25-20 04:45PM	Biohaven Pharmaceuticals Reports Fourth Quarter And Full Year 2019 Financial Results And Recent Business Developments PR Newswire
Feb-14-20 07:33AM	Kleo Pharmaceuticals Elects CEO Doug Manion, MD, FCRP (C), New Chairman of the Board PR Newswire
Feb-11-20 11:27AM	3 Beaten-Down Biotech Stocks With +50% Upside Potential TipRanks
Feb-10-20 04:17PM	Biotech Stock Crumbles After Drug Fails To Pass Muster In Anxiety Investor's Business Daily -8.18%
08:10AM	Biohaven's investigational anxiety drug fails in trial MarketWatch
07:30AM	Biohaven's Rimegepant Named To Cortellis 2020 Potential Blockbuster "Drugs to Watch" List PR Newswire
07:25AM	Biohaven's Troriluzole Study For Generalized Anxiety Disorder (GAD) Misses Primary Endpoint PR Newswire
Feb-06-20 07:33AM	Kleo Pharmaceuticals Receives IND Authorization to Proceed from FDA for its Multiple Myeloma Therapeutic PR Newswire
Feb-04-20 10:22AM	Analysts Forecast Huge Upsides for Aimmune, Biohaven GuruFocus.com +6.56%
Jan-31-20 05:00PM	Biohaven Appoints Michael Heffernan To Board Of Directors PR Newswire
Jan-30-20 09:02AM	Options Traders Expect Huge Moves in Biohaven Pharmaceutical (BHVN) Stock Zacks
Jan-29-20 07:34AM	Biohaven Announces Pricing Of $250 Million Public Offering Of Common Shares PR Newswire -9.82%

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders and Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in phase III trial for multiple system atrophy. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was founded in 2013 and is headquartered in New Haven, Connecticut.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Coric Vlad	Chief Executive Officer	Jan 06	Option Exercise	0.00	12,500	0	25,211	Jan 08 08:48 PM
Conway Charles	Chief Scientific Officer	Jan 06	Option Exercise	0.00	3,750	0	11,759	Jan 08 08:48 PM
Engelhart James	Chief Financial Officer	Jan 06	Option Exercise	0.00	3,750	0	10,958	Jan 08 08:48 PM
Gentile Kimberly	SVP, Clinical Operations	Jan 06	Option Exercise	0.00	3,750	0	9,438	Jan 08 08:48 PM
Stock Elyse	Chief Medical Officer	Jan 06	Option Exercise	0.00	1,250	0	2,187	Jan 08 08:49 PM
Stock Elyse	Chief Medical Officer	Jan 06	Option Exercise	0.00	3,750	0	7,438	Jan 08 08:49 PM
JONES WILLIAM A JR	CCO-Migraine & Common Disease	Jan 06	Option Exercise	0.00	5,000	0	9,251	Jan 08 08:49 PM
Tilton John	Chief Commercial Officer	Jan 06	Option Exercise	0.00	1,250	0	3,151	Jan 08 08:49 PM
Conway Charles	Chief Scientific Officer	Nov 25	Option Exercise	0.00	3,000	0	8,639	Nov 27 09:47 PM
Coric Vlad	Chief Executive Officer	Nov 25	Option Exercise	0.00	10,950	0	16,935	Nov 27 09:47 PM
Engelhart James	Chief Financial Officer	Nov 25	Option Exercise	0.00	3,700	0	8,222	Nov 27 09:47 PM
Gentile Kimberly	SVP, Clinical Operations	Nov 25	Option Exercise	0.00	3,750	0	7,389	Nov 27 09:48 PM
JONES WILLIAM A JR	CCO-Migraine & Common Disease	Nov 25	Option Exercise	0.00	3,000	0	4,755	Nov 27 09:48 PM
Stock Elyse	Chief Medical Officer	Nov 25	Option Exercise	0.00	3,375	0	5,219	Nov 27 09:48 PM
Tilton John	Chief Commercial Officer	Nov 25	Option Exercise	0.00	1,250	0	2,020	Nov 27 09:48 PM
CHILDS JOHN W	Director	Nov 23	Buy	89.55	5,000	447,737	2,516,938	Nov 23 08:40 PM
JONES WILLIAM A JR	CCO-Migraine & Common Disease	Nov 02	Option Exercise	50.72	30,000	1,521,600	31,755	Nov 04 08:31 PM
JONES WILLIAM A JR	CCO-Migraine & Common Disease	Nov 02	Sale	76.22	30,000	2,286,676	1,755	Nov 04 08:31 PM
Bailey Gregory	Director	Oct 23	Sale	78.91	10,403	820,866	2,545,658	Oct 23 09:25 PM
Bailey Gregory	Director	Oct 22	Sale	79.47	24,566	1,952,352	2,556,061	Oct 23 09:25 PM
Bailey Gregory	Director	Oct 19	Sale	78.98	4,554	359,655	2,580,627	Oct 21 09:24 PM
Bailey Gregory	Director	Oct 16	Sale	78.88	3,748	295,638	2,585,181	Oct 21 09:24 PM
Bailey Gregory	Director	Oct 12	Sale	78.87	6,729	530,740	2,588,929	Oct 14 09:31 PM
Gentile Kimberly	SVP, Clinical Operations	Oct 08	Option Exercise	9.29	23,500	218,315	27,139	Oct 09 06:42 PM
Gentile Kimberly	SVP, Clinical Operations	Oct 08	Sale	76.34	23,500	1,794,082	3,639	Oct 09 06:42 PM
CHILDS JOHN W	Director	Sep 21	Buy	59.25	3,322	196,828	2,511,938	Sep 22 09:51 PM
CHILDS JOHN W	Director	Sep 11	Buy	59.00	6,678	393,984	2,508,616	Sep 14 08:49 PM
CHILDS JOHN W	Director	Aug 11	Buy	61.54	25,000	1,538,485	2,501,938	Aug 12 06:25 PM
Berman Robert	Special Projects & Med Ovrsght	Jul 08	Option Exercise	0.61	58,404	35,626	58,745	Jul 10 09:15 PM
Bailey Gregory	Director	Jul 08	Sale	75.22	50,000	3,760,765	2,595,658	Jul 10 09:16 PM
Berman Robert	Special Projects & Med Ovrsght	Jul 08	Sale	75.25	58,404	4,394,890	341	Jul 10 09:15 PM
Bailey Gregory	Director	Jun 24	Sale	69.86	3,995	279,090	2,645,658	Jun 25 09:49 PM
Berman Robert	Special Projects & Med Ovrsght	Jun 23	Option Exercise	0.61	4,296	2,621	4,637	Jun 25 09:49 PM
Berman Robert	Special Projects & Med Ovrsght	Jun 23	Sale	75.05	4,296	322,431	341	Jun 25 09:49 PM
Bailey Gregory	Director	Jun 23	Sale	74.15	101,643	7,536,432	2,649,653	Jun 25 09:49 PM
Bailey Gregory	Director	Jun 22	Sale	73.24	80,331	5,883,175	2,751,296	Jun 22 09:58 PM
Berman Robert	Special Projects & Med Ovrsght	Jun 19	Option Exercise	0.61	986	601	1,327	Jun 22 09:57 PM
Bailey Gregory	Director	Jun 19	Sale	71.22	164,031	11,682,757	2,831,627	Jun 22 09:58 PM
Berman Robert	Special Projects & Med Ovrsght	Jun 19	Sale	75.07	986	74,016	341	Jun 22 09:57 PM
Berman Robert	Special Projects & Med Ovrsght	Jun 18	Option Exercise	2.64	61,314	162,152	61,655	Jun 22 09:57 PM
Berman Robert	Special Projects & Med Ovrsght	Jun 18	Sale	75.27	61,314	4,615,290	341	Jun 22 09:57 PM
Gentile Kimberly	SVP, Clinical Operations	Jun 17	Option Exercise	5.60	24,000	134,400	27,639	Jun 17 09:55 PM
Gentile Kimberly	SVP, Clinical Operations	Jun 17	Option Exercise	5.60	400	2,240	4,039	Jun 18 09:51 PM
Gentile Kimberly	SVP, Clinical Operations	Jun 17	Sale	70.20	400	28,081	3,639	Jun 18 09:51 PM
Gentile Kimberly	SVP, Clinical Operations	Jun 17	Sale	70.20	24,000	1,684,870	3,639	Jun 17 09:55 PM
Doogan Declan	Director	Jun 16	Sale	68.22	60,000	4,092,959	626,002	Jun 17 09:55 PM
Doogan Declan	Director	Jun 15	Sale	66.73	80,000	5,338,791	686,002	Jun 17 09:55 PM
Stock Elyse	Chief Medical Officer	Jun 12	Option Exercise	25.90	36,966	957,511	38,810	Jun 12 09:51 PM
Stock Elyse	Chief Medical Officer	Jun 12	Sale	64.83	36,966	2,396,502	1,844	Jun 12 09:51 PM
Doogan Declan	Director	Jun 12	Sale	64.73	80,000	5,178,453	766,002	Jun 12 08:09 PM
Engelhart James	Chief Financial Officer	Jun 11	Option Exercise	9.29	19,772	183,682	24,294	Jun 12 05:19 PM
Doogan Declan	Director	Jun 11	Sale	63.41	80,000	5,072,600	846,002	Jun 12 08:09 PM
Engelhart James	Chief Financial Officer	Jun 11	Sale	63.43	19,772	1,254,057	4,522	Jun 12 05:19 PM
Tilton John	Chief Commercial Officer	Jun 10	Option Exercise	9.29	52,000	483,080	52,770	Jun 12 05:19 PM
Engelhart James	Chief Financial Officer	Jun 10	Option Exercise	4.76	53,953	257,073	58,475	Jun 12 05:19 PM
Tilton John	Chief Commercial Officer	Jun 10	Sale	67.38	52,000	3,504,001	770	Jun 12 05:19 PM
Engelhart James	Chief Financial Officer	Jun 10	Sale	67.07	53,953	3,618,545	4,522	Jun 12 05:19 PM
Gentile Kimberly	SVP, Clinical Operations	Jun 08	Option Exercise	5.60	600	3,360	4,239	Jun 10 09:24 PM
Gentile Kimberly	SVP, Clinical Operations	Jun 08	Sale	70.05	600	42,027	3,639	Jun 10 09:24 PM
Bailey Gregory	Director	Jun 05	Option Exercise	4.69	438,200	2,053,938	3,025,801	Jun 08 05:15 PM
CHILDS JOHN W	Director	Apr 07	Sale	31.91	200,000	6,381,032	2,476,938	Apr 08 09:42 PM
CHILDS JOHN W	Director	Apr 06	Sale	31.25	150,000	4,686,937	2,676,938	Apr 08 09:42 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience